MAKERSLMakers Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Makers Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations in India. It operates in two segments, Pharmaceutical and Chemical Manufacturing. The company offers general health therapeutic products, including acid regulatory, anthelmintic, anti-allergic, anti-asthmatic, anti-biotic, anti-diabetics, anti-diarrhoeals, anti-emetics and anti-nauseants, anti-fungal, anti-hypertensive, antiinflammatory, analgesic, anti-spasmodic, anti-malarial, and anti-thyroid. It also provides cough and cold control, digestives, neurotonics, nutritional supplements, topical anti-biotic/anti-microbial, and other specialty drugs. The company sells its products under the Duramol, Artemak-AB, Loroquin, Nimuwin, Coffwin, and Exylin brands. It distributes its products through agents, stockiest, doctors, and retailers. The company also exports its products. Makers Laboratories Limited was incorporated in 1984 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on MAKERSL — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 22.2% YoY
- • Profit growth: 244.6% YoY
- • Debt/Equity: 0.05
- • Sector momentum: sector +6.2% (1m)
- • Max drawdown (1y): 19%
Bull case
- • Revenue growth: 22.2% YoY
- • Profit growth: 244.6% YoY
- • Debt/Equity: 0.05
- • Sector momentum: sector +6.2% (1m)
Bear case
- • Recently listed — limited trading history, scores are provisional
- • ROE: 3.2%
- • Dividend yield: 0.00%
- • Insufficient price history
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Recently listed — limited trading history, scores are provisional
- • ROE: 3.2%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹11.79). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.